000130304 001__ 130304
000130304 005__ 20240228143423.0
000130304 0247_ $$2doi$$a10.1016/j.ccell.2016.02.011
000130304 0247_ $$2pmid$$apmid:26977882
000130304 0247_ $$2pmc$$apmc:PMC4794752
000130304 0247_ $$2ISSN$$a1535-6108
000130304 0247_ $$2ISSN$$a1878-3686
000130304 0247_ $$2altmetric$$aaltmetric:6188781
000130304 037__ $$aDKFZ-2017-05383
000130304 041__ $$aeng
000130304 082__ $$a610
000130304 1001_ $$aPei, Yanxin$$b0
000130304 245__ $$aHDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
000130304 260__ $$aCambridge, Mass.$$bCell Press$$c2016
000130304 3367_ $$2DRIVER$$aarticle
000130304 3367_ $$2DataCite$$aOutput Types/Journal article
000130304 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522135521_18537
000130304 3367_ $$2BibTeX$$aARTICLE
000130304 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130304 3367_ $$00$$2EndNote$$aJournal Article
000130304 520__ $$aMedulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MYC-driven MB has a particularly poor prognosis and would greatly benefit from more effective therapies. We used an animal model of MYC-driven MB to screen for drugs that decrease viability of tumor cells. Among the most effective compounds were histone deacetylase inhibitors (HDACIs). HDACIs potently inhibit survival of MYC-driven MB cells in vitro, in part by inducing expression of the FOXO1 tumor suppressor gene. HDACIs also synergize with phosphatidylinositol 3-kinase inhibitors to inhibit tumor growth in vivo. These studies identify an effective combination therapy for the most aggressive form of MB.
000130304 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000130304 588__ $$aDataset connected to CrossRef, PubMed,
000130304 650_7 $$2NLM Chemicals$$aForkhead Transcription Factors
000130304 650_7 $$2NLM Chemicals$$aHistone Deacetylase Inhibitors
000130304 650_7 $$2NLM Chemicals$$aProto-Oncogene Proteins c-myc
000130304 650_7 $$0EC 2.7.1.-$$2NLM Chemicals$$aPhosphatidylinositol 3-Kinases
000130304 650_7 $$0EC 3.5.1.98$$2NLM Chemicals$$aHistone Deacetylases
000130304 7001_ $$aLiu, Kun-Wei$$b1
000130304 7001_ $$aWang, Jun$$b2
000130304 7001_ $$aGarancher, Alexandra$$b3
000130304 7001_ $$aTao, Ran$$b4
000130304 7001_ $$aEsparza, Lourdes A$$b5
000130304 7001_ $$aMaier, Donna L$$b6
000130304 7001_ $$aUdaka, Yoko T$$b7
000130304 7001_ $$aMurad, Najiba$$b8
000130304 7001_ $$aMorrissy, Sorana$$b9
000130304 7001_ $$0P:(DE-HGF)0$$aSeker-Cin, Huriye$$b10
000130304 7001_ $$0P:(DE-He78)b0b3740107f746e09dc23fdf25eb0629$$aBrabetz, Sebastian$$b11$$udkfz
000130304 7001_ $$aQi, Lin$$b12
000130304 7001_ $$aKogiso, Mari$$b13
000130304 7001_ $$aSchubert, Simone$$b14
000130304 7001_ $$aOlson, James M$$b15
000130304 7001_ $$aCho, Yoon-Jae$$b16
000130304 7001_ $$aLi, Xiao-Nan$$b17
000130304 7001_ $$aCrawford, John R$$b18
000130304 7001_ $$aLevy, Michael L$$b19
000130304 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b20$$udkfz
000130304 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b21$$udkfz
000130304 7001_ $$aTaylor, Michael D$$b22
000130304 7001_ $$aWechsler-Reya, Robert J$$b23
000130304 773__ $$0PERI:(DE-600)2074034-7$$a10.1016/j.ccell.2016.02.011$$gVol. 29, no. 3, p. 311 - 323$$n3$$p311 - 323$$tCancer cell$$v29$$x1535-6108$$y2016
000130304 909CO $$ooai:inrepo02.dkfz.de:130304$$pVDB
000130304 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000130304 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b0b3740107f746e09dc23fdf25eb0629$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000130304 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000130304 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000130304 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000130304 9141_ $$y2016
000130304 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER CELL : 2015
000130304 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130304 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130304 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130304 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130304 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130304 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130304 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130304 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130304 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130304 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130304 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130304 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130304 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bCANCER CELL : 2015
000130304 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000130304 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000130304 980__ $$ajournal
000130304 980__ $$aVDB
000130304 980__ $$aI:(DE-He78)B062-20160331
000130304 980__ $$aI:(DE-He78)L101-20160331
000130304 980__ $$aUNRESTRICTED